Nemaura Medical Receives Analyst Coverage

Posted on February 18, 2021 by Aaron Warwick

Nemaura Medical (NMRD), a medical device company with a non-invasive continuous glucose monitoring (CGM) system, today received its first analyst coverage. Ascendiant Capital rated NMRD as a “Buy” with a $15 price target. NMRD was first covered by Breakout Investors on February 3.

Although NMRD is currently “pre-revenue,” they are expected to sign at least one large deal in 1H 2021, which alone could put the company at break-even. NMRD is clearly prepared to ramp sales, with two excellent recent hires to lead their sales teams in the United States and the United Kingdom, respectively.

Disclosure: I am long NMRD and may buy or sell shares at any time.

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x